Treatment-Resistant Depression Market Report 2026

The treatment-resistant depression market size has grown strongly in recent years. It will grow from $1.87 billion in 2025 to $2 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to rising prevalence of major depressive disorder, limited efficacy of conventional antidepressants, increased diagnosis of refractory depression cases, expansion of psychiatric specialty clinics, growing acceptance of advanced mental health therapies.

The treatment-resistant depression market size is expected to see strong growth in the next few years. It will grow to $2.59 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing investments in precision psychiatry, growing approval of ketamine and esketamine therapies, expansion of biomarker-driven treatment selection, rising demand for long-term depression management solutions, increased use of digital therapeutic support tools. Major trends in the forecast period include increasing adoption of novel rapid-acting antidepressants, rising use of neuromodulation therapies, growing focus on personalized psychiatry approaches, expansion of psychedelic-based treatment research, enhanced integration of digital mental health tools.

The high prevalence of mental disorders is expected to drive the growth of the treatment-resistant depression market in the coming years. Mental disorders encompass a wide range of conditions that affect an individual’s cognitive, emotional, and behavioral functioning, often causing significant distress and impairing daily life. Factors such as genetic predisposition contribute to the high prevalence, as inherited genetic variations can influence brain chemistry and increase susceptibility to conditions like depression, anxiety, and schizophrenia. Treatment-resistant depression (TRD) supports patients with mental disorders by promoting the use of more personalized and advanced therapies when standard treatments are ineffective, improving recovery outcomes and quality of life. For example, in November 2023, the American Psychological Association (APA) reported that among adults, those aged 18 to 34 had the highest rate of mental illnesses at 50%, while adults aged 35 to 44 saw the largest increase in diagnoses, with 45% reporting a mental illness. Consequently, the high prevalence of mental disorders is fueling the growth of the treatment-resistant depression market.

Key companies in the treatment-resistant depression market are focusing on developing innovative therapies, such as monotherapy, to address unmet patient needs, enhance efficacy, and reduce side effects. Monotherapy involves using a single treatment or medication to manage a condition, rather than combining multiple therapies. It aids in treating treatment-resistant depression by providing a focused approach that may be more effective for patients who have not responded to multiple medications. For instance, in January 2025, Johnson & Johnson Services Inc., a U.S.-based pharmaceutical, biotechnology, and medical technology company, announced that the U.S. Food and Drug Administration (FDA) approved SPRAVATO (esketamine) nasal spray, a fast-acting treatment for adults with treatment-resistant depression (TRD). SPRAVATO is used in combination with an oral antidepressant for patients who have not adequately responded to at least two other antidepressant therapies. Its rapid action addresses the limitations of traditional antidepressants, which often take weeks to produce results. As a ketamine derivative, esketamine targets NMDA receptors in the brain, potentially improving mood within hours. This approval represented a major advancement in mental health treatment.

In October 2024, Resilience Lab, a U.S.-based healthcare company, acquired Options MD for an undisclosed amount. Through this acquisition, Resilience Lab aims to enhance its mental health service offerings by integrating Options MD’s specialized treatment platform for severe and treatment-resistant depression, thereby expanding access to personalized and evidence-based care. Options MD is a U.S.-based telepsychiatry company providing treatment for severe and treatment-resistant depression (TRD), bipolar disorder, post-traumatic stress disorder (PTSD), and other mental health conditions.

Major companies operating in the treatment-resistant depression market are Pfizer Inc., Johnson & Johnson Services Inc., Neurocrine Biosciences Inc., Relmada Therapeutics Inc., Neuronetics Inc., COMPASS Pathways, BrainsWay Ltd., Magstim Company Limited, MindMed, Alto Neuroscience, Sage Therapeutics Inc., MindBio Therapeutics Ltd., Reunion Neuroscience.

North America was the largest region in the treatment-resistant depression market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the treatment-resistant depression market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the treatment-resistant depression market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the treatment-resistant depression market by increasing costs of imported active pharmaceutical ingredients, neuromodulation devices, medical electronics, and specialty drug formulations. North America and Europe are most affected due to dependence on imported psychiatric drugs and device components, while Asia-Pacific faces higher costs for clinical research materials. These tariffs are contributing to higher treatment costs and slower adoption of advanced therapies. At the same time, they are supporting domestic drug manufacturing, local device assembly, and increased investment in regional mental health innovation ecosystems.

The treatment-resistant depression market research report is one of a series of new reports that provides treatment-resistant depression market statistics, including treatment-resistant depression industry global market size, regional shares, competitors with a treatment-resistant depression market share, detailed treatment-resistant depression market segments, market trends and opportunities, and any further data you may need to thrive in the treatment-resistant depression industry. This treatment-resistant depression market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Treatment-resistant depression (TRD) is a severe and persistent form of major depressive disorder (MDD) marked by an insufficient response to at least two different antidepressant therapies of adequate dose and duration, resulting in prolonged psychological distress and impaired functioning. Individuals with TRD often require advanced treatment strategies, including novel pharmacological therapies, neuromodulation techniques, and personalized mental health interventions, to achieve symptom relief and enhance overall well-being.

The primary drug classes in treatment-resistant depression include selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors, tricyclic antidepressants, psychedelics, and others. Selective serotonin reuptake inhibitors (SSRIs) are antidepressant medications that work by increasing serotonin levels in the brain through inhibition of its reabsorption into neurons, thereby improving mood regulation and addressing conditions such as depression and anxiety disorders. These drugs are administered via routes such as oral, parenteral, and others, and are distributed through channels including hospital pharmacies, retail pharmacies, and online pharmacies to end users such as hospitals, homecare settings, specialty clinics, and others.

The treatment-resistant depression market consists of revenues earned by entities by providing services such as psychiatric counseling, cognitive behavioral therapy (CBT), transcranial magnetic stimulation (TMS) therapy, electroconvulsive therapy (ECT), and ketamine infusion therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The treatment-resistant depression market includes sales of products such as esketamine nasal spray, vagus nerve stimulation (VNS) devices, deep brain stimulation (DBS) systems, neuromodulation devices, glutamate receptor modulators, and digital therapeutics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.